Markus Hartenfeller

Heidelberg Engineering (Germany) — Germany

Computer Science · Physical Sciences

11h-index962citations24works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(13), Chemical Synthesis and Analysis(9), Click Chemistry and Applications(6), Microbial Natural Products and Biosynthesis(4), BRCA gene mutations in cancer(3)

Publications24 total

BRCA variant classification of ClinVar submitter content from ENIGMA, ARUP laboratories and German cancer consortium compared to MH BRCA® and correlation with response to PARP inhibition in MH GUIDE®
European Journal of Cancer·2020
Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
International Journal of Molecular Sciences·2020· 4 citedOpen Access
BRCA variant classification is improved by Japanese SNP data and correlate with response to PARP inhibition in MH GUIDE
Annals of Oncology·2019
Confident BRCA1/2 variant classification: using ACMG and public data for systematic molecular profiling
Annals of Oncology·2018Open Access
Abstract A1-33: Knowledge prioritization of cancer genomes using oncoscores and functional impact scores to support biomarker discovery and clinical decision making
Cancer Research·2015
Abstract P3-06-22: Identification of ERBB2 gene variants in HER2 positive disease associated with trastuzumab response in an adjuvant trastuzumab chemotherapy trial
Cancer Research·2015
Abstract A41: Automated retrieval and assessment of biomarker-related evidence for cancer treatment decision support
Clinical Cancer Research·2015
Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulators
Chemical Communications·2015· 10 citedOpen Access
Reaction‐Driven <i>De Novo</i> Design: a Keystone for Automated Design of Target Family‐Oriented Libraries
2013· 4 cited
Wirkstoffe nach Zahlen: reaktionsbasierter De‐novo‐Entwurf von potenten und selektiven Leitstrukturen für die Krebsforschung
Angewandte Chemie·2012· 9 cited
Drugs by Numbers: Reaction‐Driven De Novo Design of Potent and Selective Anticancer Leads
Angewandte Chemie International Edition·2012· 26 cited
Probing the Bioactivity-Relevant Chemical Space of Robust Reactions and Common Molecular Building Blocks
Journal of Chemical Information and Modeling·2012· 40 cited
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
PLoS Computational Biology·2012· 261 citedOpen Access
A Collection of Robust Organic Synthesis Reactions for <i>In Silico</i> Molecule Design
Journal of Chemical Information and Modeling·2011· 119 cited
Enabling future drug discovery by <i>de novo</i> design
Wiley Interdisciplinary Reviews Computational Molecular Science·2011· 87 cited
Reaction-Driven <i>De Novo</i> Design, Synthesis and Testing of Potential Type II Kinase Inhibitors
Future Medicinal Chemistry·2011· 40 cited
‘Fuzziness’ in pharmacophore-based virtual screening and de novo design
Drug Discovery Today Technologies·2010· 26 cited
Multistep Virtual Screening for Rapid and Efficient Identification of Non‐Nucleoside Bacterial Thymidine Kinase Inhibitors
Chemistry - A European Journal·2010· 8 cited
Concepts and Applications of &amp;#x201C;Natural Computing&amp;#x201D; Techniques in De Novo Drug and Peptide Design
Current Pharmaceutical Design·2010· 29 cited
De novo Drug Design
2010· 5 cited
page 1 of 2Next →

Frequent Co-authors

Gisbert Schneider(16), Ewgenij Proschak(6), Petra Schneider(5), Theodoros Soldatos(5), Francesca Diella(5), Heiko Zettl(4), Steffen Renner(4), Michael Reutlinger(4), Udo Schmidt-Edelkraut(4), Stephan Hettich(4), Stephan Brock(4), David Jackson(4), Felix Reisen(3), Edgar Jacoby(3), Sarah Keppner(3), Birgit Spänkuch(3), Tiago Rodrigues(3), Ram Narang(3), Sajo Kaduthanam(3), Alexander Zien(3)